Microcap Ledger Jade Biosciences, Inc. $JBIO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Fiscal year end
- December 31
- Shares outstanding
- 63,597,387 [10-Q 2026-08-10]
What the company doesAI summary of filing
Jade Biosciences is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for autoimmune diseases. The company's lead candidate, JADE101, targets APRIL to treat IgA nephropathy and entered Phase 1 testing in healthy volunteers in August 2025; JADE201 targets BAFF-R for multiple autoimmune disorders and is planned to enter Phase 1 testing in rheumatoid arthritis patients in the second quarter of 2026; and JADE301 targets an undisclosed pathway with Phase 1 planned for the first half of 2027. The company is pre-revenue and generates no current income, instead incurring research and development costs through agreements with Paragon Therapeutics for antibody discovery and with WuXi Biologics for manufacturing and development services. [10-K 2026-03-06]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$96.13M | −$67.74M | $107.25M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | — | −$127.41M | −$94.69M | $88.44M | [10-K 2026-03-06] |
| FY ended Dec 2024 | — | −$69.63M | −$71.20M | $69.39M | [10-K 2025-03-27] |
- Quarterly cash burn
- −$33.87M
- Cash runway Estimate
- ~9.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 28,874,513 | [10-Q 2024-11-12] |
| 2025-03-24 | 28,985,019 | [10-K 2025-03-27] |
| 2025-04-24 | 28,985,019 | [10-Q 2025-04-25] |
| 2025-08-08 | 32,626,730 | [10-Q 2025-08-13] |
| 2025-11-07 | 46,004,205 | [10-Q 2025-11-14] |
| 2026-02-28 | 49,316,287 | [10-K 2026-03-06] |
| 2026-05-01 | 49,359,875 | [10-Q 2026-05-07] |
| 2026-08-03 | 63,597,387 | [10-Q 2026-08-10] |
- Shelf registration
- S-3 filed 2026-05-07; declared effective 2026-05-15 [S-3 2026-05-07]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2024-10-17. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2024-10-17 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-10-17] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-02-12 | Dahms Bradford D. | grant | 37,813 | — | [4 2026-02-13] |
| 2026-02-12 | Balta Elizabeth | grant | 28,125 | — | [4 2026-02-13] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-30 | 8-K | Other events |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-08-10 | 8-K | Results of operations |
| 2026-07-17 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-08 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-01 | 8-K | Material agreement entered |
| 2026-06-26 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-06-11 | 8-K | Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-06-09 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-04 | 8-K | Other events |
Alerts for $JBIO
Email me when Jade Biosciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.